

# Peter B Berger

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11922274/peter-b-berger-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224 papers	25,445 citations	73 h-index	157 g-index
240 ext. papers	28,305 ext. citations	9 avg, IF	6.14 L-index

#	Paper	IF	Citations
224	Sex differences in the treatment and outcomes of patients hospitalized with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 95, 196-204	2.7	4
223	Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007097	6	0
222	Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 123-130	16.2	18
221	Plasma Ceramides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 1933-1939	9.4	97
220	Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2. <i>Circulation</i> , <b>2018</b> , 137, 376-387	16.7	65
219	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1824-1833 <sup>23</sup>	5.4	23
218	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 190-198	2.7	12
217	Impact of pre-hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST-segment elevation myocardial infarction network. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 245-251	2.7	15
216	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	23
215	Changes in Percutaneous Coronary Interventions Deemed "Inappropriate" by Appropriate Use Criteria. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1234-1242	15.1	21
214	Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics. <i>American Heart Journal</i> , <b>2017</b> , 186, 118-126	4.9	4
213	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	10
212	Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2017</b> , 227, 808-812	3.2	15
211	Cyclosporine for Reperfusion Injury After Cardiac Arrest: Too Little Too Late?. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 566-7	16.2	1
210	Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , <b>2016</b> , 37, 1284-95	9.5	38
209	Paroxysmal atrial fibrillation and the hazards of under-treatment. <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 214-20	3.2	12
208	Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality. <i>Medical Care</i> , <b>2016</b> , 54, 538-45	3.1	3

207	Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1036-46	5	35
206	Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and Outcomes. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9, e003586	6	36
205	Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. <i>Circulation</i> , <b>2016</b> , 134, 365-74	16.7	63
204	Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 8-14	5.8	95
203	Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8, e001712	6	10
202	Reply: Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease?. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1716	15.1	
201	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , <b>2015</b> , 170, 706-14	4.9	4
200	Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?. <i>Journal of Interventional Cardiology</i> , <b>2015</b> , 28, 223-32	1.8	17
199	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. <i>EuroIntervention</i> , <b>2015</b> , 11, 196-203	3.1	27
198	Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 276-83	5	12
197	Is the heat on HEAT-PPCI appropriate?. <i>Lancet, The</i> , <b>2014</b> , 384, 1824-1826	40	8
196	Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. <i>American Heart Journal</i> , <b>2014</b> , 168, 537-44	4.9	18
195	Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1724-34	15.1	88
194	Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2717-26	15.1	45
193	Comparison of intermediate-term outcomes of coronary artery bypass grafting versus drug-eluting stents for patients $\geq$ 5 years of age. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 803-8	3	22
192	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , <b>2013</b> , 382, 1714-22	40	405
191	Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort. <i>Journal of Interventional Cardiology</i> , <b>2013</b> , 26, 14-21	1.8	13
190	Readmission in the 30 days after percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 237-44	5	39

189	The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. <i>Urology</i> , <b>2013</b> , 82, 773-9	1.6	11
188	Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2013</b> , 6, 354-61	6	44
187	Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e004564	6	35
186	Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. <i>Journal of Interventional Cardiology</i> , <b>2013</b> , 26, 623-9	1.8	2
185	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , <b>2012</b> , 33, 2143-50	9.5	73
184	Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 423-8	5.8	86
183	Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 77-81	6	26
182	Response to Letters Regarding Article, Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. <i>Circulation</i> , <b>2012</b> , 125, 1132-7	16.7	1
181	Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 272-9	15.1	75
180	Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 572-84	7	152
179	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1980-9	59.2	230
178	Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. <i>American Heart Journal</i> , <b>2011</b> , 161, 360-6	4.9	18
177	Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , <b>2011</b> , 162, 98-105.e1	4.9	32
176	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 579-85	6.1	3
175	Allergic reactions to clopidogrel and cross-reactivity to other agents. <i>Current Allergy and Asthma Reports</i> , <b>2011</b> , 11, 52-7	5.6	31
174	P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?. <i>Current Cardiology Reports</i> , <b>2011</b> , 13, 320-6	4.2	1
173	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. <i>Circulation</i> , <b>2011</b> , 124, 1132-7	16.7	331
172	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1097-105	27.4	959

171	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 522-34	6	88
170			
169	Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 284-7; discussion 288	6	1
168	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>Circulation</i> , <b>2010</b> , 121, 2575-83	16.7	173
167	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 582-7	9.5	48
166	The glycoprotein IIb/IIIa inhibitor wars: an update. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 476-8	15.1	8
165	Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 742-50	5	11
164	Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 163-7	3	22
163	Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1527-33	3	39
162	Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 920-7	5	111
161	Intracoronary glycoprotein IIb/IIIa inhibitors from questioning the logic to weighing the data. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 935-6	5	3
160	Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2009</b> , 2, 503-12	6	21
159	Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. <i>Circulation</i> , <b>2009</b> , 120, 2337-44	16.7	110
158	Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1258-63	3	90
157	Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 1285-91	3	7
156	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , <b>2009</b> , 157, 369-74	4.9	63
155	Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. <i>American Heart Journal</i> , <b>2009</b> , 157, 651-7	4.9	38
154	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , <b>2009</b> , 157, 818-24, 824.e1	4.9	92

153	ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. <i>American Heart Journal</i> , <b>2009</b> , 158, 400-409	4.9	5
152	The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1935-45	15.1	103
151	Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. <i>Circulation: Cardiovascular Interventions</i> , <b>2009</b> , 2, 348-51	6	27
150	Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 379-86	8	126
149	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2009</b> , 30, 290-6	9.5	44
148	Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. <i>Journal of Invasive Cardiology</i> , <b>2009</b> , 21, 194-200	0.7	7
147	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 299S-339S	5.3	621
146	Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 690-7	15.1	381
145	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , <b>2008</b> , 155, 687-93	4.9	144
144	Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. <i>Cerebrovascular Diseases</i> , <b>2008</b> , 25, 344-7	3.2	20
143	Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 94-102		68
142	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>European Heart Journal</i> , <b>2008</b> , 29, 455-61	9.5	43
141	Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. <i>Circulation</i> , <b>2008</b> , 118, 632-8	16.7	53
140	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 688-96	59.2	287
139	The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 776S-814S	5.3	196
138	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 26, 8-13	5.1	8
137	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , <b>2008</b> , 97, 160-8	6.1	11
136	Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. <i>Catheterization and Cardiovascular Interventions</i> , <b>2008</b> , 72, 815-8	2.7	14



135	Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , <b>2008</b> , 31, 128-35	3.3	1
134	Investigating the mechanisms of hyporesponse to antiplatelet approaches. <i>Clinical Cardiology</i> , <b>2008</b> , 31, 121-7	3.3	7
133	Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. <i>Clinical Cardiology</i> , <b>2008</b> , 31, 12-9	3.3	9
132	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. <i>Journal of Lipid Research</i> , <b>2007</b> , 48, 425-33	6.3	178
131	Perioperative management of patients with coronary stents. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 2145-50	15.1	157
130	Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1982-8	15.1	638
129	Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1752-8	15.1	91
128	Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 349-52	3	24
127	Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. <i>Journal of Electrocardiology</i> , <b>2007</b> , 40, 265-70	1.4	31
126	The risk of drug-eluting stent thrombosis with noncardiac surgery. <i>Current Cardiology Reports</i> , <b>2007</b> , 9, 406-11	4.2	15
125	Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 2371-80	27.4	258
124	Bleeding is bad.... isn't it?. <i>Circulation</i> , <b>2007</b> , 116, 2776-8	16.7	9
123	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , <b>2007</b> , 82, 301-307	6.4	10
122	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. <i>American Heart Journal</i> , <b>2007</b> , 154, 158.e1-7	4.9	19
121	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. <i>American Heart Journal</i> , <b>2007</b> , 154, 3-11	4.9	86
120	Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease. <i>Mayo Clinic Proceedings</i> , <b>2007</b> , 82, 301-7	6.4	15
119	Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 1172-6	3	39
118	Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 1537-56	5.8	14

117	Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1531-8	27.4	561
116	Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. <i>Circulation</i> , <b>2006</b> , 114, 2040-6	16.7	32
115	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1706-17	59.2	2120
114	Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 939-43	15.1	145
113	Cardiogenic shock--Beyond the large infarction. <i>Critical Care Medicine</i> , <b>2006</b> , 34, 2234-5	1.4	34
112	Review: Early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. <i>ACP Journal Club</i> , <b>2006</b> , 145, 61		
111	Therapeutic goals for effective platelet inhibition: a consensus document. <i>Reviews in Cardiovascular Medicine</i> , <b>2006</b> , 7, 214-25	3.9	4
110	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. <i>European Heart Journal</i> , <b>2005</b> , 26, 1379-84	9.5	41
109	Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 46-57	59.2	545
108	Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. <i>European Heart Journal</i> , <b>2005</b> , 26, 137-44	9.5	199
107	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. <i>American Heart Journal</i> , <b>2005</b> , 149, 869-75	4.9	44
106	Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. <i>American Heart Journal</i> , <b>2005</b> , 150, 796-9	4.9	7
105	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , <b>2005</b> , 150, 401	4.9	27
104	Variability in platelet responsiveness to clopidogrel among 544 individuals. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 246-51	15.1	630
103	In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 349-54	3	42
102	Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 1218-22	3	267
101	Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 512-4	3	74
100	Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2005</b> , 19, 11-8	5.1	29



99	Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , <b>2005</b> , 111, 940-53	16.7	187
98	Renal function, concomitant medication use and outcomes following acute coronary syndromes. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 2105-12	4.3	53
97	A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 232-8	59.2	481
96	Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?. <i>Circulation</i> , <b>2004</b> , 109, 1079-81	16.7	15
95	Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 2051-7		118
94	Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 2096-104	27.4	412
93	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 623-5	3	30
92	Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2004</b> , 17, 11-20	5.1	1
91	Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2004</b> , 18, 25-30	5.1	1
90	Transport and centralization of acute coronary syndrome care. <i>Current Cardiology Reports</i> , <b>2004</b> , 6, 292-94.2		
89	Can percutaneous coronary interventions reduce death and myocardial infarction in stable and unstable coronary disease?. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 61, 528-36	2.7	2
88	Resistance to antiplatelet drugs: is it real or relevant?. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 62, 43-5	2.7	3
87	Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1786-91	15.1	18
86	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 2133-6	15.1	125
85	Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. <i>American Heart Journal</i> , <b>2004</b> , 147, 463-7	4.9	163
84	Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. <i>American Heart Journal</i> , <b>2004</b> , 147, 1066-70	4.9	33
83	Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. <i>American Heart Journal</i> , <b>2004</b> , 147, 815-22	4.9	80
82	Cardiovascular disease and chronic kidney disease: insights and an update. <i>American Heart Journal</i> , <b>2004</b> , 148, 230-42	4.9	58

81	Percutaneous Coronary Intervention for ST-Segment and Non-ST-Segment Elevation Myocardial Infarction at Hospitals With and Without On-site Cardiac Surgical Capability. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 738-744	6.4	18
80	Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1786-1791	15.1	56
79	Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. <i>Circulation</i> , <b>2003</b> , 108, 921-4	16.7	216
78	Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). <i>Circulation</i> , <b>2003</b> , 107, 2331-6	16.7	35
77	Management of patients undergoing percutaneous coronary revascularization. <i>Annals of Internal Medicine</i> , <b>2003</b> , 139, 123-36	8	66
76	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 330-3	3	29
75	Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. <i>Atherosclerosis</i> , <b>2003</b> , 168, 315-22	3.1	45
74	Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 234-40	15.1	366
73	Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 1188-95	15.1	88
72	Clinical safety of magnetic resonance imaging early after coronary artery stent placement. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 1295-8	15.1	65
71	Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. <i>American Heart Journal</i> , <b>2003</b> , 146, 345-50	4.9	41
70	ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Circulation</i> , <b>2002</b> , 105, 1257-1267	16.7	496
69	The thienopyridines. <i>Journal of Interventional Cardiology</i> , <b>2002</b> , 15, 85-93	1.8	20
68	Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 2411-20	27.4	2289
67	Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. <i>Circulation</i> , <b>2002</b> , 106, 2284-7	16.7	38
66	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 9-14	15.1	249
65	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Journal of the American College of</i>	15.1	507
64	<i>The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 1113-9	15.1	575

63	Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 1881-9	15.1	28
62	Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1567-72	15.1	120
61	Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. <i>Atherosclerosis</i> , <b>2002</b> , 165, 375-81	3.1	12
60	Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. <i>Evidence-based Cardiovascular Medicine</i> , <b>2002</b> , 6, 137-138		
59	Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. <i>American Heart Journal</i> , <b>2002</b> , 143, 841-6	4.9	33
58	Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. <i>Circulation</i> , <b>2002</b> , 105, 2259-64	16.7	1275
57	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Circulation</i> , <b>2002</b> , 105, 1257-67	16.7	161
56	Effectiveness and safety of abciximab after failed thrombolytic therapy. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 439-42, A4	3	18
55	Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 630-3, A9	3	48
54	An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 1100-2, A6, A9	3	48
53	Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 1091-6	3	90
52	Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: what's behind this new lexicon and what does it add?. <i>Circulation</i> , <b>2001</b> , 104, 627-9	16.7	24
51	Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. <i>Circulation</i> , <b>2001</b> , 103, 2572-8	16.7	323
50	Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 1448-9	15.1	68
49	A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 1608-13	15.1	34
48	Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. <i>American Heart Journal</i> , <b>2001</b> , 141, 47-54	4.9	39
47	Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). <i>American Heart Journal</i> , <b>2001</b> , 142, 301-8	4.9	56
46	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. <i>American Heart Journal</i> , <b>2001</b> , 142, 452-9	4.9	46

45	Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). <i>American Heart Journal</i> , <b>2001</b> , 142, 776-81	4.9	5
44	Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 890-6	6.4	8
43	Hemorrhagic and Vascular Complications After Percutaneous Coronary Intervention With Adjunctive Abciximab. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 890-896	6.4	19
42	Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. <i>Circulation</i> , <b>2000</b> , 101, 2795-802	16.7	136
41	Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , <b>2000</b> , 1, 83-87		13
40	Application of the New York State PTCA mortality model in patients undergoing stent implantation. <i>Circulation</i> , <b>2000</b> , 102, 517-22	16.7	48
39	Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis. <i>Circulation</i> , <b>2000</b> , 101, E211-2	16.7	
38	Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. <i>American Journal of Medicine</i> , <b>2000</b> , 108, 187-92	2.4	63
37	Immediate and one-year outcome of intracoronary stent implantation in small coronary arteries with 2.5-mm stents. <i>American Heart Journal</i> , <b>2000</b> , 140, 898-905	4.9	2
36	Cardiogenic shock complicating acute coronary syndromes. <i>Lancet, The</i> , <b>2000</b> , 356, 749-56	40	144
35	Improving outcome over time of percutaneous coronary interventions in unstable angina. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 674-8	15.1	23
34	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 2168-73	15.1	98
33	Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. <i>Circulation</i> , <b>1999</b> , 99, 248-53	16.7	86
32	Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. <i>Circulation</i> , <b>1999</b> , 100, 2353-8	16.7	63
31	One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. <i>Circulation</i> , <b>1999</b> , 99, 873-8	16.7	75
30	Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. <i>Circulation</i> , <b>1999</b> , 100, 14-20	16.7	462
29	Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. <i>Circulation</i> , <b>1999</b> , 100, 2067-73	16.7	173
28	The thienopyridines in coronary artery disease. <i>Current Cardiology Reports</i> , <b>1999</b> , 1, 192-8	4.2	10

27	Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. <i>American Journal of Cardiology</i> , <b>1999</b> , 83, 1006-11	3	74
26	Clopidogrel versus ticlopidine after intracoronary stent placement. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 1891-4	15.1	132
25	Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction. <i>American Heart Journal</i> , <b>1998</b> , 135, 310-7	4.9	74
24	Noninvasive prediction of residual blood flow within the risk area during acute myocardial infarction: a multicenter validation study of patients undergoing direct coronary angioplasty. <i>American Heart Journal</i> , <b>1997</b> , 134, 639-46	4.9	8
23	Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. <i>Lancet, The</i> , <b>1997</b> , 349, 75-8	4.0	81
22	Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 30, 676-81	15.1	25
21	Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. <i>American Journal of Cardiology</i> , <b>1997</b> , 79, 1005-11	3	53
20	Interventional cardiology and intracoronary stents--a changing practice: approved vs. nonapproved indications. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1997</b> , 40, 133-8		15
19	Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. <i>Circulation</i> , <b>1997</b> , 95, 1222-7	16.7	139
18	Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCA TOP). <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 27, 1-7	15.1	47
17	Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 28, 361-7	15.1	48
16	Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 28, 1732-7	15.1	19
15	Impact of stent size and indication for stent placement on immediate outcome. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1996</b> , 38, 145-51		2
14	Referral for coronary artery revascularization procedures after diagnostic coronary angiography: evidence for gender bias?. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 25, 1650-5	15.1	73
13	Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 26, 668-74	15.1	300
12	Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. <i>American Journal of Cardiology</i> , <b>1995</b> , 76, 565-9	3	19
11	Management of balloon rupture during rigid stent deployment. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1995</b> , 35, 211-5		10
10	Long-term outcome of women compared with men after successful coronary angioplasty. <i>Circulation</i> , <b>1995</b> , 91, 2876-81	16.7	60

9	A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. <i>Circulation</i> , <b>1995</b> , 91, 1966-74	16.7	134
8	Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1994</b> , 73, 231-6	3	39
7	Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction. <i>International Journal of Cardiology</i> , <b>1993</b> , 38, 151-8	3.2	5
6	Use of excimer laser in the treatment of chronic total occlusion of a coronary artery that cannot be crossed with a balloon catheter. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1993</b> , 28, 44-6		8
5	Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. <i>American Journal of Cardiology</i> , <b>1993</b> , 71, 1148-52	3	92
4	Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 20, 533-40	15.1	89
3	Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 449-54	3	37
2	Balloon angioplasty of chronic total coronary artery occlusions: what does it cost in radiation exposure, time, and materials?. <i>Catheterization and Cardiovascular Diagnosis</i> , <b>1992</b> , 25, 10-5		56
1	Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists95-110		